ArticleThe Journal of clinical endocrinology and metabolism2025
Continuous Glucose Monitoring in the Management of Congenital Hyperinsulinism: A National User-satisfaction Survey, UK.
Article in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Continuous glucose monitoring in early gestational diabetes improves maternal and neonatal outcomes-The Steady Sugar trial.Diabetes, obesity & metabolism · 2026Trial
- Knowledge, attitudes, and practices in pediatric hypoglycemia in Italy (KAPPHy study).Journal of endocrinological investigation · 2026Article
- Continuous Glucose Monitoring in the Management of Congenital Hyperinsulinism: A National User-satisfaction Survey, UK.The Journal of clinical endocrinology and metabolism · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextCongenital hyperinsulinism (CHI) causes severe and recurrent hypoglycemia with a 33% to 50% risk of neurodisability necessitating rigorous glucose monitoring. Continuous glucose monitoring (CGM) is now widely used in CHI with limited data on user-reported benefits. There are no validated instruments available to assess the impact of CGM use on quality of life (QOL) in CHI.
objectiveTo evaluate CGM user satisfaction of patients with CHI and their carers.
designModified CGM-satisfaction (CGM-SAT) and glucose monitoring surveys (GMS) were distributed electronically to CHI families using CGM.
settingCHI highly specialized services, UK, May to August 2023. PATIENTS OR OTHER
participantsParents (n = 86) and teachers (n = 15) of patients with CHI using CGM (0-18 years old) and patients themselves if ≥7 years old (n = 20).
main outcome measuresUser-reported ease of CGM handling, influence of CGM on CHI management and QOL, and desire for continued use of CGM.
resultsMost respondents reacted positively to statements regarding: CGM device handling (58% agreed or strongly agreed), influence on CHI management (70%), QOL (75%), and continued use (86%). Satisfaction with CGM was positively correlated with duration of use (r = 0.40, P < 0.001). Eighty-six percent of users reported checking the CGM 1 to 5 times per hour. Users reported perceived improvements in safety, hypoglycemia detection, freedom, and independence, despite concerns with accuracy and device range.
conclusionPatients with CHI and their carers reported that they feel safer and perceive benefits from CGM in all aspects of living with CHI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.